Protocol for a randomised controlled trial of vasopressin versus noradrenaline as initial therapy in septic sHock (VANISH)

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  Gordon, Anthony C ^a,b   Mason, Alexina J ^c   Perkins, Gavin D ^d,e   Ashby, Deborah ^c   Brett, Stephen J ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; NORADRENALIN; PLACEBO; VASOPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SURVEILLANCE PROGRAM; FEASIBILITY STUDY; HEMATOLOGIC DISEASE; HUMAN; INFUSION RATE; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVAL RATE; UNITED KINGDOM; CLINICAL TRIAL; COMPARATIVE STUDY; METHODOLOGY; PROSPECTIVE STUDY; SHOCK, SEPTIC;

DOUBLE-BLIND METHOD; HUMANS; NOREPINEPHRINE; PROSPECTIVE STUDIES; RESEARCH DESIGN; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 84903701243     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005866     Document Type: Article

References (33)

1. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep 2005;53:1-48.
2. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006;10:R42.
3. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-53. (Pubitemid 43145611)
4. [No authors listed]. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
5. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22. (Pubitemid 24171030)
6. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5. (Pubitemid 27097820)
7. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82. (Pubitemid 34193495)
8. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989;256(2 Pt 2):F274 -8.
9. Bomzon L, Rosendorff C. Renovascular resistance and noradrenaline. Am J Physiol 1975;229:1649-53.
10. Thibonnier M, Conarty DM, Preston JA, et al. Human vascular endothelial cells express oxytocin receptors. Endocrinology 1999;140:1301-9. (Pubitemid 29104234)
11. Jin HK, Chen YF, Yang RH, et al. Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide. Am J Med Sci 1989;298:227-36.
12. Okamura T, Ayajiki K, Fujioka H, et al. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertens 1999;17:673-8. (Pubitemid 29243500)
13. Suzuki Y, Satoh S, Oyama H, et al. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo. Stroke 1993;24:1049-53.
14. Oyama H, Suzuki Y, Satoh S, et al. Role of nitric oxide in the cerebral vasodilatory responses to vasopressin and oxytocin in dogs. J Cereb Blood Flow Metab 1993;13:285-90. (Pubitemid 23067463)
15. Serpa Neto A, Nassar APJ, Cardoso SO, et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care 2012;16:R154.
16. Polito A, Parisini E, Ricci Z, et al. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Med 2012;38:9-19.
17. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60.
18. Russell JA, Walley KR, Singer J, et al. Vasopressin versus noradrenaline infusion in patients with septic shock. N Engl J Med 2008;358:877-87. (Pubitemid 351397087)
19. Mehta S, Granton J, Gordon AC, et al. Cardiac ischemia in patients with septic shock randomized to vasopressin or noradrenaline. Crit Care 2013;17:R117.
20. Gordon AC, Wang N, Walley KR, et al. The cardiopulmonary effects of vasopressin compared with noradrenaline in septic shock. Chest 2012;142:593-605.
21. Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010;36:83-91.
22. Parrillo JE. Septic shock - vasopressin, noradrenaline, and urgency. N Engl J Med 2008;358:954-6. (Pubitemid 351397096)
23. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-18.
24. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
25. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-75.
26. Minneci PC, Deans KJ, Eichacker PQ, et al. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009;15:308-18.
27. Gordon AC, Mason AJ, Perkins GD, et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 2014;42:1325-33.
28. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
29. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
30. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
31. Kenward MG, Carpenter J. Multiple imputation: current perspectives. Stat Methods Med Res 2007;16:199-218. (Pubitemid 47018659)
32. Daniels MJ, Hogan JW, eds. Missing data in longitudinal studies: strategies for Bayesian modeling and sensitivity analysis. 1st edn. Chapman and Hall, 2008.
33. Harvey SE, Elbourne D, Ashcroft J, et al. Informed consent in clinical trials in critical care: experience from the PAC-Man Study. Intensive Care Med 2006;32:2020-5. (Pubitemid 44833116)